Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Emerging migraine treatments and drug targets.

Olesen J, Ashina M.

Trends Pharmacol Sci. 2011 Jun;32(6):352-9. doi: 10.1016/j.tips.2011.02.016. Review.

PMID:
21459461
2.

Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs.

Lynch JJ, Shen YT, Pittman TJ, Anderson KD, Koblan KS, Gould RJ, Regan CP, Kane SA.

Eur J Pharmacol. 2009 Nov 25;623(1-3):96-102. doi: 10.1016/j.ejphar.2009.09.018.

PMID:
19766109
3.

Emerging treatment for chronic migraine and refractory chronic migraine.

Lionetto L, Negro A, Palmisani S, Gentile G, Del Fiore MR, Mercieri M, Simmaco M, Smith T, Al-Kaisy A, Arcioni R, Martelletti P.

Expert Opin Emerg Drugs. 2012 Sep;17(3):393-406. doi: 10.1517/14728214.2012.709846. Review.

PMID:
22862686
4.
5.

Future drugs for migraine.

Farinelli I, De Filippis S, Coloprisco G, Missori S, Martelletti P.

Intern Emerg Med. 2009 Oct;4(5):367-73. doi: 10.1007/s11739-009-0273-0. Review.

PMID:
19551474
6.

The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors.

Gupta S, Villalón CM.

Pharmacol Ther. 2010 Oct;128(1):170-90. doi: 10.1016/j.pharmthera.2010.06.005. Review.

PMID:
20655327
7.

Emerging target-based paradigms to prevent and treat migraine.

Silberstein SD.

Clin Pharmacol Ther. 2013 Jan;93(1):78-85. doi: 10.1038/clpt.2012.198. Review.

PMID:
23212108
8.

Migraine: emerging treatment options for preventive and acute attack therapy.

Goadsby PJ.

Expert Opin Emerg Drugs. 2006 Sep;11(3):419-27. Review.

PMID:
16939382
9.

[Strategies for antimigraine agents].

Ishii T, Taniguchi H, Saito A.

Nihon Yakurigaku Zasshi. 2008 Mar;131(3):205-9. Review. No abstract available.

PMID:
18344603
10.

Future trends in drugs for migraine prophylaxis.

Barbanti P, Aurilia C, Egeo G, Fofi L.

Neurol Sci. 2012 May;33 Suppl 1:S137-40. doi: 10.1007/s10072-012-1058-1. Review.

PMID:
22644189
11.

New therapeutic approaches for the prevention and treatment of migraine.

Diener HC, Charles A, Goadsby PJ, Holle D.

Lancet Neurol. 2015 Oct;14(10):1010-22. doi: 10.1016/S1474-4422(15)00198-2. Review.

PMID:
26376968
12.

Emerging therapies for migraine.

Goadsby PJ.

Nat Clin Pract Neurol. 2007 Nov;3(11):610-9. Review.

PMID:
17982431
13.

Future pharmacologic targets for acute and preventive treatments of migraine.

Buchanan TM, Ramadan NM, Aurora S.

Expert Rev Neurother. 2004 May;4(3):391-430. Review.

PMID:
15853537
14.

Sumatriptan iontophoretic transdermal system for the acute treatment of migraine.

Vikelis M, Mitsikostas DD, Rapoport AM.

Pain Manag. 2014 Mar;4(2):123-8. doi: 10.2217/pmt.13.71. Review.

PMID:
24641436
15.

Novel migraine therapy with calcitonin gene-regulated peptide receptor antagonists.

Edvinsson L.

Expert Opin Ther Targets. 2007 Sep;11(9):1179-88. Review.

PMID:
17845144
16.

Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors.

Tajti J, Csáti A, Vécsei L.

Expert Opin Drug Metab Toxicol. 2014 Nov;10(11):1509-20. doi: 10.1517/17425255.2014.963554. Review.

PMID:
25253587
17.

Current and prospective pharmacological targets in relation to antimigraine action.

Mehrotra S, Gupta S, Chan KY, Villalón CM, Centurión D, Saxena PR, MaassenVanDenBrink A.

Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):371-94. doi: 10.1007/s00210-008-0322-7. Review.

PMID:
18626630
18.

Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study.

Dahlöf CG, Hauge AW, Olesen J.

Cephalalgia. 2009 Nov;29 Suppl 2:7-16. doi: 10.1111/j.1468-2982.2009.01975.x.

PMID:
19723121
19.

Calcitonin gene-related peptide receptor antagonists for the treatment of migraine: a patent review.

Paone DV, Staas DD.

Expert Opin Ther Pat. 2009 Dec;19(12):1675-713. doi: 10.1517/13543770903359822. Review.

PMID:
19939188
20.

Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis.

Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG; Tonabersat TON-01-05 Study Group..

Cephalalgia. 2009 Jul;29(7):742-50. doi: 10.1111/j.1468-2982.2008.01804.x.

PMID:
19222510
Items per page

Supplemental Content

Support Center